Hikma Pharmaceuticals Share Price (HIK)
| Bid price | 1,208.00 | Open price | 1,187.50 |
|---|---|---|---|
| Ask price | 1,209.50 | Prev close | 1,208.00 |
| High price | 1,248.00 | Spread | 0.12% |
| Low price | 1,183.35 | Volume | 649,028 |
Register now for FREE live Hikma Pharmaceuticals share prices, Hikma Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hikma Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hikma Pharmaceuticals (HIK) and other London Stock Exchange equities.
Hikma Pharmaceuticals Share Price Chart
Register now for FREE Hikma Pharmaceuticals share price charts
Hikma Pharmaceuticals Share Price Information
| Name | Hikma Pharmaceuticals | Epic | HIK |
|---|---|---|---|
| Sector | Pharmaceuticals & Biotechnology | ISIN | GB00B0LCW083 |
| Activites | Hikma Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'njectables, Generics and Branded, based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million. | Index | FTSE 250 |
Hikma Pharmaceuticals Key Numbers
| Latest Share Price (p) | 1,208.00 | Net Gearing (%) | 48.20 |
|---|---|---|---|
| Market Capitalisation (£m) | 2,853.07 | Gross Gearing (%) | 54.90 |
| Shares in issue (m) | 240.87 | Debt Ratio | 41.03 |
| P/E Ratio | -3.37 | Debt-to-Equity Ratio | 0.57 |
| Total dividends per share (p) | 34.00 | Assets / Equity Ratio | 2.22 |
| Dividend Yield (%) | 1.84 | Price to book value | 1.87 |
| Dividend cover (x) | 0.00 | ROCE (%) | -28.48 |
| Earning per share (p) | -351.80 | EPS Growth (%) | -629.02 |
| 52 week high / low | 2,000.00 / 814.20 | DPS Growth (%) | 3.03 |
Hikma Pharmaceuticals Director Deals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 19/03/2018 | TIN | Mazen Darwazah | ED | 38,501 |
| 19/03/2018 | TIN | Said Darwazah | CH | 68,346 |
| 31/05/2017 | TIN | Mazen Darwazah | ED | 38,088 |
| 31/05/2017 | TIN | Said Darwazah | CH | 52,164 |
| 15/05/2017 | TIN | Mazen Darwazah | ED | 30,000 |
Hikma Pharmaceuticals Company News
Hikma launches injection to reduce severity of cardiomyopathy
Hikma Pharmaceuticals said Friday its wholly-owned US subsidiary West-Ward Pharmaceuticals launched an injection to reduce the incidence and severity of cardiomyopathy, a chronic heart disease, in certain women with breast cancer. West-Ward launched Dexrazoxane for injection, the generic...
Hikma launches Dexrazoxane for Injection
RNS Number : 5333L Hikma Pharmaceuticals Plc 20 April 2018 London, 20 April 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that its wholly-owned US subsidiary West-Ward...
Annual Financial Report and Notice of AGM
RNS Number : 4724L Hikma Pharmaceuticals Plc 19 April 2018 Hikma Pharmaceuticals PLC (the 'Company') Publication of 2017 Annual Report and Notice of AGM LEI: 549300BNS685UXH4JI75 The Company will today publish on its website, www.hikma.com , the Annual...
More Hikma Pharmaceuticals Company News >>
Register now for FREE Hikma Pharmaceuticals company news
Hikma Pharmaceuticals Share Price Discussions
Hikma Pharmaceuticals (HIK)
Floated in London last November at 290p (FTSE-250). Company website www.hikma.com Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals Geographic markets: USA, Europe and the Middle East & North Africa...
Register now for FREE Hikma Pharmaceuticals share price discussions